Development asset linked to Théa Pharma Ireland in public FDA and regional records.
pharma · cystic fibrosis · Relapsing Multiple Sclerosis (relapsing-remitting, relapsing-progressive)
Théa Pharma Ireland
Verona Pharma Ireland Limited
Théa Pharma Ireland drug portfolio — 42 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Castlebar, IE HQ
2018 Founded
19 Employees
EMA registrant Type
Company details
- Status
- Public
- HQ
- Castlebar, IE
- Founded
- 2018
- Employees
- 19
- Programs
- 11
- Drugs
- 42
- Patents
- 0
Théa Pharma Ireland pipeline
Portfolio lens on 42 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Théa Pharma Ireland drug portfolio — 42 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
US regulatory status: approved.
-
Development asset linked to Théa Pharma Ireland in public FDA and regional records.
-
Development asset linked to Théa Pharma Ireland in public FDA and regional records.
-
US regulatory status: approved. Mechanism: Unknown.
- Mechanism
- Unknown
-
Development asset linked to Théa Pharma Ireland in public FDA and regional records.
-
Development asset linked to Théa Pharma Ireland in public FDA and regional records.
-
US regulatory status: approved. Molecular target: DNA.
- Target
- DNA
- Mechanism
- DNA inhibitor
-
Development asset linked to Théa Pharma Ireland in public FDA and regional records. Mechanism: Serotonin transporter inhibitor.
- Mechanism
- Serotonin transporter inhibitor
-
docetaxel
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Tubulin.
- Target
- Tubulin
- Mechanism
- Tubulin inhibitor
-
Development asset linked to Théa Pharma Ireland in public FDA and regional records.
-
doxorubicin
Antineoplastic and immunomodulating agents (L01)Antineoplastic and immunomodulating agents (L01) compound in Théa Pharma Ireland's portfolio. Mechanism: DNA topoisomerase II alpha inhibitor.
- Mechanism
- DNA topoisomerase II alpha inhibitor
-
doxorubicin hydrochloride
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: DNA.
- Target
- DNA
- Mechanism
- DNA topoisomerase II alpha inhibitor
-
US regulatory status: approved. Molecular target: Vitamin D3 receptor.
- Target
- Vitamin D3 receptor
- Mechanism
- Vitamin D receptor agonist
-
US regulatory status: approved. Molecular target: Bacterial 70S ribosome.
- Target
- Bacterial 70S ribosome
- Mechanism
- Bacterial 70S ribosome inhibitor
-
Development asset linked to Théa Pharma Ireland in public FDA and regional records. Mechanism: Serotonin transporter inhibitor.
- Mechanism
- Serotonin transporter inhibitor
-
US regulatory status: approved. Molecular target: Sodium-dependent serotonin transporter.
- Target
- Sodium-dependent serotonin transporter
- Mechanism
- Serotonin transporter inhibitor
-
US regulatory status: approved. Molecular target: DNA.
- Target
- DNA
- Mechanism
- Thymidylate synthase inhibitor
-
Development asset linked to Théa Pharma Ireland in public FDA and regional records.
-
Development asset linked to Théa Pharma Ireland in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Synaptosomal-associated protein 25.
- Target
- Synaptosomal-associated protein 25
- Mechanism
- Synaptosomal-associated protein 25 inhibitor
-
Development asset linked to Théa Pharma Ireland in public FDA and regional records.
-
Development asset linked to Théa Pharma Ireland in public FDA and regional records.
-
nivolumab
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Programmed cell death protein 1.
- Target
- Programmed cell death protein 1
- Mechanism
- Programmed cell death protein 1 inhibitor
-
olaparib
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: PARP 1, 2 and 3.
- Target
- PARP 1, 2 and 3
- Mechanism
- PARP 1, 2 and 3 inhibitor
-
US regulatory status: approved. Molecular target: DNA.
- Target
- DNA
- Mechanism
- DNA inhibitor
-
ozanimod
Antineoplastic and immunomodulating agents (L04)US regulatory status: approved. Molecular target: Sphingosine 1-phosphate receptor 5.
- Target
- Sphingosine 1-phosphate receptor 5
- Mechanism
- Sphingosine 1-phosphate receptor Edg-1 modulator
-
US regulatory status: approved. Molecular target: Sphingosine 1-phosphate receptor 1.
- Target
- Sphingosine 1-phosphate receptor 1
- Mechanism
- Sphingosine 1-phosphate receptor Edg-1 modulator
-
Development asset linked to Théa Pharma Ireland in public FDA and regional records.
-
Development asset linked to Théa Pharma Ireland in public FDA and regional records.
-
safinamide
Nervous system (N04)US regulatory status: approved. Molecular target: Amine oxidase [flavin-containing] B.
- Target
- Amine oxidase [flavin-containing] B
- Mechanism
- Monoamine oxidase B inhibitor
-
US regulatory status: approved. Molecular target: Amine oxidase [flavin-containing] B.
- Target
- Amine oxidase [flavin-containing] B
- Mechanism
- Monoamine oxidase B inhibitor
-
US regulatory status: approved. Molecular target: Sodium-dependent serotonin transporter.
- Target
- Sodium-dependent serotonin transporter
- Mechanism
- Serotonin transporter inhibitor
-
siponimod
Antineoplastic and immunomodulating agents (L04)US regulatory status: approved. Molecular target: Sphingosine 1-phosphate receptor 1.
- Target
- Sphingosine 1-phosphate receptor 1
- Mechanism
- Sphingosine 1-phosphate receptor Edg-1 agonist
-
Development asset linked to Théa Pharma Ireland in public FDA and regional records. Molecular target: Sphingosine 1-phosphate receptor 1.
- Target
- Sphingosine 1-phosphate receptor 1
- Mechanism
- Sphingosine 1-phosphate receptor Edg-1 agonist
-
Development asset linked to Théa Pharma Ireland in public FDA and regional records.
-
Development asset linked to Théa Pharma Ireland in public FDA and regional records.
-
Development asset linked to Théa Pharma Ireland in public FDA and regional records.
-
Development asset linked to Théa Pharma Ireland in public FDA and regional records.
-
Development asset linked to Théa Pharma Ireland in public FDA and regional records.
-
Development asset linked to Théa Pharma Ireland in public FDA and regional records.
-
vortioxetine
Nervous system (N06)US regulatory status: approved. Mechanism: Serotonin 3a (5-HT3a) receptor antagonist.
- Mechanism
- Serotonin 3a (5-HT3a) receptor antagonist